Macrogenics Inc (NAS:MGNX)
$ 4.36 0.25 (6.07%) Market Cap: 273.08 Mil Enterprise Value: 107.83 Mil PE Ratio: 0 PB Ratio: 2.57 GF Score: 60/100

Zymeworks Inc and MacroGenics Inc at Citi BioPharma Conference - Co Panel: Bispecific Panel Transcript

Sep 07, 2022 / 06:40PM GMT
Release Date Price: $4.23 (+4.19%)
Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst

So let's start. Welcome back, everyone. I think everyone knows me. I'm Yigal Nochomovitz, one of the biotech analyst at Citi. I cover both these distinguished companies. So welcome both of you. Scott Koenig, CEO, MacroGenics; and not [Neal Joseph], Ken from Zymeworks. So welcome both to you.

Scott Koenig
MacroGenics, Inc. - President, CEO & Director

Thank you.

Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst

Great. Great to have you here.

Kenneth H. Galbraith
Zymeworks Inc. - CEO & Chairman of the Board

Pleasure.

Yigal Dov Nochomovitz
Citigroup Inc. Exchange Research - Research Analyst

So I think for those who are less familiar with both of your companies, we could just start with a quick 2- to 3-minute overview of the pipeline. What are the -- highlight the key assets, maybe some of the key clinical trials you're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot